Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Nature Medicine

Volumn 20, Issue 9, 2014, Pages 1027-1034

  Lovly, Christine M ^a   McDonald, Nerina T ^a   Chen, Heidi ^a   Ortiz Cuaran, Sandra ^b   Heukamp, Lukas C ^b,c   Yan, Yingjun ^a   Florin, Alexandra ^b   Ozretić, Luka ^b   Lim, Diana ^d   Wang, Lu ^d   Chen, Zhao ^e   Chen, Xi ^a   Lu, Pengcheng ^a   Paik, Paul K ^d   Shen, Ronglai ^d   Jin, Hailing ^a   Buettner, Reinhard ^b   Ansén, Sascha ^b   Perner, Sven ^a   Brockmann, Michael ^g   Bos, Marc ^b   Wolf, Jürgen ^b   Gardizi, Masyar ^f   Wright, Gavin M ^h   Solomon, Benjamin ⁱ   Russell, Prudence A ^j   Rogers, Toni Maree ⁱ   Suehara, Yoshiyuki ^d   Red Brewer, Monica ^a   Tieu, Rudy ^d   De Stanchina, Elisa ^d   Wang, Qingguo ^k   Zhao, Zhongming ^k   Johnson, David H ^l   Horn, Leora ^a   Wong, Kwok Kin ^e   Thomas, Roman K ^b   Ladanyi, Marc ^d   Pao, William ^a   more..

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c NEO New Oncology GmbH   (Germany)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g Hospital Merheim   (Germany)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

^j ST VINCENT S HOSPITAL   (Australia)

^k VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; ANAPLASTIC LYMPHOMA RECEPTOR TYROSINE KINASE; ANAPLASTIC LYMPHOMA RECEPTOR TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; CERITINIB; CRIZOTINIB; ERLOTINIB; INSULIN RECEPTOR SUBSTRATE 1; MONOCLONAL ANTIBODY; PEMETREXED; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; X 376; ANAPLASTIC LYMPHOMA KINASE; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; DRUG TARGETING; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; MONOTHERAPY; PRIORITY JOURNAL; TUMOR BIOPSY; UPREGULATION; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENE SILENCING; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED;

FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; LUNG NEOPLASMS; MIDDLE AGED; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; UP-REGULATION;

EID: 84908363886     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3667     Document Type: Article

References (32)

1. Grande, E., Bolos, M.V., Arriola, E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol. Cancer Ther. 10, 569-579 (2011).
2. Camidge, D.R. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011-1019 (2012).
3. Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra117 (2012).
4. Doebele, R.C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472-1482 (2012).
5. Lovly, C.M., Pao, W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci. Transl. Med. 4, 120ps122 (2012).
6. Tanizaki, J. et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin. Cancer Res. 18, 6219-6226 (2012).
7. Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
8. Shaw, A.T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253 (2009).
9. Boik, J.C., Newman, R.A., Boik, R.J. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study. Stat. Med. 27, 1040-1061 (2008).
10. Mulvihill, M.J. et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 1, 1153-1171 (2009).
11. Metz, H.E., Houghton, A.M. Insulin receptor substrate regulation of phosphoinositide 3-kinase. Clin. Cancer Res. 17, 206-211 (2011).
12. Yang, X. et al. Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res. 71, 5965-5975 (2011).
13. Chen, Z. et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 70, 9827-9836 (2010).
14. Lovly, C.M. et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 71, 4920-4931 (2011).
15. Katayama, R. et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl. Acad. Sci. USA 108, 7535-7540 (2011).
16. Guix, M. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118, 2609-2619 (2008).
17. Cortot, A.B. et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 73, 834-843 (2013).
18. Garciá-Echeverria, C. et al. In vivo antitumor activity of NVP-AEW541-a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5, 231-239 (2004).
19. Morgillo, F. et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin. Cancer Res. 13, 2795-2803 (2007).
20. Vazquez-Martin, A. et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci. Rep. 3, 2560 (2013).
21. Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011).
22. Ohashi, K. et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl. Acad. Sci. USA 109, E2127-E2133 (2012).
23. Suehara, Y. et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin. Cancer Res. 18, 6599-6608 (2012).
24. Shaw, A.T. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189-1197 (2014).
25. Galkin, A.V. et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. USA 104, 270-275 (2007).
26. Morris, S.W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284 (1994).
27. Li, H., Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
28. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
29. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
30. Gainor, J.F. et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1, 683 patients with non-small cell lung cancer. Clin. Cancer Res. 19, 4273-4281 (2013).
31. Dunning, M.J., Smith, M.L., Ritchie, M.E., Tavare, S. Beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23, 2183-2184 (2007).
32. Su, Z. et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J. Mol. Diagn. 13, 74-84 (2011).